Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 368-374

  Sapkota, Shraddha ^a   Gee, Myrlene ^a   Sabino, Jennifer ^a   Emery, Derek ^a   Camicioli, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Brain atrophy; Homocysteine; Longitudinal study; Magnetic resonance imaging; Parkinson's disease

Indexed keywords

HOMOCYSTEINE; LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; BRAIN VENTRICLE DILATATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LABORATORY TEST; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT DURATION; ATROPHY; BRAIN; DILATATION; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ATROPHY; BRAIN; DILATATION; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84896139581     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25798     Document Type: Article

References (34)

1. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: An overview of environmental risk factors. Environ Health Perspect. 2005;113:1250-1256.
2. Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson's disease: Specific evidence in human and mammalian models. Neurobiol Dis. 2013;57:38-46.
3. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's Disease. New Engl J Med. 2005; 351: 2498-2508.
5. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease: as detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38:277-301.
6. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol. 1999;56:529-535.
7. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26:137-146.
8. Scott JM, Weir DG. Folic acid, homocysteine and one-carbon metabolisim: a review of the essential biochemistry. J Cardiovas Risk. 1998;5:223-227.
9. Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR. Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol. 2009;10:533-541.
10. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60:1125-1129.
11. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2000;55:437-440.
12. Camicioli R, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord. 2009;24:176-182.
13. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013;110:9523-9528.
14. Prins ND, den Heijer T, Hofam A, et al. Homocysteine and cognitive function in the elderly: the Rotterdram scan study. Neurology. 2002;59:1375-1380.
15. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126:170-175.
16. Rajagopalan P, Hua X, Toga AW, et al. Homocysteine effects on brain volumes mapped in 732 elderly individuals. Ageing. 2011;22:391-395.
17. Sachdev PS. Homocysteine and brain atrophy. Prog Neurpsychopharmacol Biol Psychiatry. 2005;29:1152-1161.
18. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
19. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel compression mapping of serial magnetic resonance images. Lancet. 2001;358:201-205.
20. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244.
21. Whalley LJ, Staff RT, Murray AD, et al. Plasma vitamin C, cholesterol and homocysteine are associated with grey matter volume determined by MRI in non-demented old people. Neurosci Lett. 2003;341:173-176.
22. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord. 2005;20:1571-1576.
23. Camicioli R, Sabino J, Gee M, et al. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. Mov Disord. 2011;26:1443-1450.
24. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicableto MRI and CT. Stroke. 2001;32:1318-1322.
25. Acharya HJ, Bouchard TP, Emery DJ, Camicioli RM. Axial signs and magnetic resonance imaging correlates in Parkinson's disease. Can J Neurol Sci. 2007;34:56-61.
26. O'Suilleabhain PE, Sung V, Hernandex BS, et al. Elevated plasma homocysteine level in patients with Parkinson's disease. Arch Neurol. 2004;61:865-868.
27. Erten-Lyons D, Dodge HH, Woltjer R, et al. Neuropathologic basis of age-associated brain atrophy. JAMA Neurol. 2013;70:616-622.
28. Dalaker TO, Zivadinov R, Ramasamy DP, et al. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord. 2011;26:297-301.
29. Herman T, Rosenberg-Katz K, Jacob Y, et al. White matter hyperintensities in Parkinson's disease: do they explain the disparity between the postural instability gait difficulty and tremor dominant subtypes? PLoS One. 2013;8:e55193.
30. Wilhelm J, Frieling H, von Ahsen N, Hillemacher T, Kornhuber J, Bleich S. Apolipoprotein E polymorphism, homocysteine serum levels and hippocampal volume in patients with alcoholism: an investigation of a gene-environment interaction. Pharmacogenomics J. 2008;8:117-121.
31. Jack CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures in clinical disease progression in AD. Neurology. 2004;62:591-600.
32. Weiner MF, de la Plata CM, Fields JBA, et al. Brain MRI, apolipoprotein E genotype, and plasma homocysteine in American Indian Alzheimer disease patients and Indian controls. Curr Alzheimer Res. 2009;6:52-58.
33. Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson's disease. Neurobiol Dis. 2012;46:389-392.
34. Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;67:28-36.